Archive | Of Interest

Mass spec technology by Shimadzu unveils novel approach for immunotherapy success

Japan’s Shimadzu Corporation collaborated with Drs William Redmond and Yoshinobu Koguchi of the Providence Cancer Institute…

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

U-M researchers target a protein channel in the cell’s lysosome to selectively kill cancer cells

Cancer treatments necessarily target unchecked cell growth, and selectively kill cancer cells while sparing normal…

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

ImCheck publishes comprehensive overview of the development results of its first-in-class cancer immunotherapeutic targeting BTN3A to activate V?9V?2 T cells in Science Translational Medicine

Marseille, France, October 20, 2021 – ImCheck Therapeutics announced today the publication of the preclinical…

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Discovery could help develop a new treatment strategy for patients with melanoma

A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest